Purple Biotech PPBT Stock
Purple Biotech Price Chart
Purple Biotech PPBT Financial and Trading Overview
Purple Biotech stock price | 2.49 USD |
Previous Close | 1.6 USD |
Open | 1.69 USD |
Bid | 0 USD x 1800 |
Ask | 0 USD x 1000 |
Day's Range | 1.6 - 1.69 USD |
52 Week Range | 1.32 - 2.8 USD |
Volume | 11.18K USD |
Avg. Volume | 25.95K USD |
Market Cap | 34.29M USD |
Beta (5Y Monthly) | 1.328767 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -49.9 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9 USD |
PPBT Valuation Measures
Enterprise Value | 10.24M USD |
Trailing P/E | N/A |
Forward P/E | -2.857143 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.6779661 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -0.507 |
Trading Information
Purple Biotech Stock Price History
Beta (5Y Monthly) | 1.328767 |
52-Week Change | -38.22% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.8 USD |
52 Week Low | 1.32 USD |
50-Day Moving Average | 1.86 USD |
200-Day Moving Average | 1.91 USD |
PPBT Share Statistics
Avg. Volume (3 month) | 25.95K USD |
Avg. Daily Volume (10-Days) | 29.58K USD |
Shares Outstanding | 21.01M |
Float | 19.59M |
Short Ratio | 34.36 |
% Held by Insiders | 0% |
% Held by Institutions | 0.86% |
Shares Short | 677.67K |
Short % of Float | N/A |
Short % of Shares Outstanding | 3.23% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -21.21% |
Return on Equity (ttm) | -36.72% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -120000 USD |
EBITDA | -20215000 USD |
Net Income Avi to Common (ttm) | -19249000 USD |
Diluted EPS (ttm) | -1.07 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 23.12M USD |
Total Cash Per Share (mrq) | 1.17 USD |
Total Debt (mrq) | 467K USD |
Total Debt/Equity (mrq) | 0.99 USD |
Current Ratio (mrq) | 4.346 |
Book Value Per Share (mrq) | 2.36 |
Cash Flow Statement
Operating Cash Flow (ttm) | -17599000 USD |
Levered Free Cash Flow (ttm) | -10137125 USD |
Profile of Purple Biotech
Country | United States |
State | N/A |
City | Rehovot |
Address | 4 Oppenheimer Street |
ZIP | 7670104 |
Phone | 972 3 933 3121 |
Website | https://purple-biotech.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 20 |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Q&A For Purple Biotech Stock
What is a current PPBT stock price?
Purple Biotech PPBT stock price today per share is 2.49 USD.
How to purchase Purple Biotech stock?
You can buy PPBT shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Purple Biotech?
The stock symbol or ticker of Purple Biotech is PPBT.
Which industry does the Purple Biotech company belong to?
The Purple Biotech industry is Biotechnology.
How many shares does Purple Biotech have in circulation?
The max supply of Purple Biotech shares is 2.65M.
What is Purple Biotech Price to Earnings Ratio (PE Ratio)?
Purple Biotech PE Ratio is now.
What was Purple Biotech earnings per share over the trailing 12 months (TTM)?
Purple Biotech EPS is -49.9 USD over the trailing 12 months.
Which sector does the Purple Biotech company belong to?
The Purple Biotech sector is Healthcare.
Purple Biotech PPBT included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}